Hoitsma Elske, Faber Carin G, Drent Marjolein, Sharma Om P
Department of Neurology, Sarcoidosis Management Center, University Hospital Maastricht, Netherlands.
Lancet Neurol. 2004 Jul;3(7):397-407. doi: 10.1016/S1474-4422(04)00805-1.
Sarcoidosis is an inflammatory multisystem disorder of unknown cause. Practically no organ is immune to sarcoidosis; most commonly, in up to 90% of patients, it affects the lungs. The nervous system is involved in 5-15% of patients. Neurosarcoidosis is a serious and commonly devastating complication of sarcoidosis. Clinical diagnosis of neurosarcoidosis depends on the finding of neurological disease in multisystem sarcoidosis. As the disease can present in many different ways without biopsy evidence, solitary nervous-system sarcoidosis is difficult to diagnose. Corticosteroids are the drug of first choice. In addition, several cytotoxic drugs, including methotrexate, have been used to treat sarcoidosis. The value of new drugs such as anti-tumour necrosis factor alpha will be assessed. In this review we describe the clinical manifestations of neurosarcoidosis, diagnostic dilemmas and considerations, and therapy.
结节病是一种病因不明的炎症性多系统疾病。实际上,没有哪个器官能对结节病免疫;最常见的是,高达90%的患者会累及肺部。5%至15%的患者神经系统会受累。神经结节病是结节病一种严重且通常具有破坏性的并发症。神经结节病的临床诊断取决于在多系统结节病中发现神经系统疾病。由于该疾病在没有活检证据的情况下可能有多种不同表现,孤立性神经系统结节病很难诊断。皮质类固醇是首选药物。此外,包括甲氨蝶呤在内的几种细胞毒性药物已被用于治疗结节病。将评估抗肿瘤坏死因子α等新药的价值。在这篇综述中,我们描述了神经结节病的临床表现、诊断困境与考量以及治疗方法。